People with schizophrenia who are treated with long acting injectable antipsychotics have a 20-30% lower risk of relapse requiring readmission to hospital than people treated with equivalent oral formulations, a nationwide study assessing the real world effectiveness of these drugs has found. To read the full article, log in using your SSSFT NHS OpenAthens details